Overall complete remission rate

65% overall complete remission rate (CR + CRi), with 52% of patients achieving a CR with TECARTUS at a median study follow-up of 12.3 months1,2

Overall complete remission rate graph Overall complete remission rate graph

Pinch to zoom

  • TECARTUS provided high OCR rates, including patients who were R/R following prior treatment with blinatumomab (OCR rate=56%; n=25) or inotuzumab ozogamicin (OCR rate=67%; n=12), patients who previously relapsed following allo-SCT (OCR rate=70%; n=23), and patients who had primary refractory disease (OCR rate=72%; n=18)2

Consistent response rates demonstrated across efficacy analyses1

Response rates in ZUMA-3 trial Response rates in ZUMA-3 trial

*Of the 71 patients who were enrolled (and leukapheresed), 57 patients received lymphodepleting chemotherapy, and 55 patients received TECARTUS. 54 patients were included in the efficacy evaluable population.1


Responses were rapid2

  • In ZUMA-3, of the 35 patients who achieved CR or CRi, the median time to response was 1.5 months (range: 0.9-3.1 months)

ALL=acute lymphoblastic leukemia; allo-SCT=allogeneic stem cell transplant; CI=confidence interval; CR=complete remission; CRi=complete remission with incomplete hematologic recovery; DOR=duration of remission; ITT=intent-to-treat; mITT=modified intent-to-treat; OCR=overall complete remission; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file [1]. Kite Pharma, Inc; 2021.

Duration of remission

TECARTUS delivered a median DOR of 13.6 months with a median study follow-up of 12.3 months1

  • DOR was a secondary endpoint of the ZUMA-3 phase 2, single-arm, open-label study2
  • DOR data are descriptive and should be carefully interpreted in light of the single-arm study design

Median DOR in patients with censoring at allo-SCT3

Median DOR in patients with censoring at allo-SCT at a median study follow-up of 12.3 months Median DOR in patients with censoring at allo-SCT at a median study follow-up of 12.3 months

Pinch to zoom

  • Median DOR was not reached in patients with a CR (95% CI: 9.6, NE)1
  • DOR was generally consistent across subgroups of patients with poor risk factors (patients who received prior treatment with blinatumomab or inotuzumab ozogamicin, patients who received prior allo-SCT, and primary refractory patients)4

Approximately 55% of responders (CR/CRi)
remained in remission at 12 months3


Patients achieved the same median DOR (13.6 months) with and without censoring for subsequent allo-SCT3

  • DOR was a secondary endpoint of the ZUMA-3 phase 2, single-arm, open-label study2
  • DOR data are descriptive and should be carefully interpreted in light of the single-arm study design
  • The study was not designed to assess efficacy of subsequent allo-SCT or to make comparisons between TECARTUS and allo-SCT as no head-to-head trial has been conducted

Median DOR in patients without censoring at allo-SCT3

Median DOR in patients without censoring at allo-SCT Median DOR in patients without censoring at allo-SCT

Pinch to zoom

  • 77% of patients (n=27/35) did not receive allo-SCT following treatment with TECARTUS2

54% of responders (n=19/35) were in
ongoing remission without subsequent allo-SCT
at median follow-up of 10.5 months3

ALL=acute lymphoblastic leukemia; allo-SCT=allogeneic stem cell transplant; CI=confidence interval; CR=complete remission; CRi=complete remission with incomplete hematologic recovery; DOR=duration of remission; NE=not estimable; NR=not reached; OCR=overall complete remission; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 3. Data on file [1]. Kite Pharma, Inc; 2021. 4. Data on file [2]. Kite Pharma, Inc; 2021.